1<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "//www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> 2<html xmlns="//www.w3.org/1999/xhtml"> 3<head> 4 <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /> 5 <title>Myelin Repair Foundation</title> 6 <meta name="Keywords" content="multiple sclerosis, multiple sclerosis research, ms, ms research, myelin, myelin repair, innovative research, ms treatment, multiple sclerosis treatments" /> 7 <meta name="Description" content="The Myelin Repair Foundation is an innovative research foundation focusing on developing drug therapies for multiple sclerosis patients." /> 8 <link href='https://fonts.googleapis.com/css?family=Tinos:400,700,400italic,700italic' rel='stylesheet' type='text/css'> 9 <link href='https://fonts.googleapis.com/css?family=Fjalla+One' rel='stylesheet' type='text/css'> 10 11 <link rel="SHORTCUT ICON" href="/favicon.ico" type="image/x-icon" /> 12 <link rel="stylesheet" href="/css/screen.css?v=2026a" type="text/css" media="screen" /> 13 <link rel="stylesheet" href="/css/navigation.cssv=2022a" type="text/css" media="screen" /> 14 <!--[if lt IE 9]> 15 <link rel="stylesheet" type="text/css" href="/css/ie.css" media="screen" /> 16 <![endif]--> 17 18 <!-- IE6-8 support of HTML5 elements --> <!--[if lt IE 9]> 19
19<script src="https://html5shim.googlecode.com/svn/trunk/html5.js"></script>
19 20 <![endif]--> 21 22 <link rel="stylesheet" href="https://releases.flowplayer.org/5.3.2/skin/functional.css"/> 23 24 <link rel="stylesheet" href="/css/simple-lightbox.css?v=2022a" /> 25
25<script src="/js/simple-lightbox.js"></script>
25 26 27
27<script src="https://ajax.googleapis.com/ajax/libs/jquery/1/jquery.min.js"></script>
27 28 <meta name="google-site-verification" content="WD4rX19ay38MTcx7I_4SeFaXfPuhEUUI9LSFEo9BYF0" /> 29
29<script type="text/javascript" src="/js/jquery.cycle.lite.js"> 30 </script>
30 31
31<script type="text/javascript"> 32 $(document).ready(function(){ 33 $('#rotInner').cycle({ 34 fx: 'fade', 35 timeout: 14000, 36 pause: 1 37 }); 38 39 $('#appsFooter').show(); 40 $('.lnkCirculation').addClass('activeLink'); 41 $('.app:not(#appCirculation)').hide(); 42 43 $('#appsFooter a').click(function(e) { 44 e.preventDefault(); 45 $('#appsFooter a').removeClass('activeLink'); 46 $(this).addClass('activeLink'); 47 $('.app').hide(); 48 activeApp = $(this).attr('href'); 49 $(activeApp).show(); 50 }); 51 52 }); 53 </script>
53 54</head> 55<body class="bodyHome"> 56<div id="outerWrapper"> 57 <div id="TopBar"> 58 <div id="TopBarContainer"> 59 <div id="CallMRF"> 60 Collaboration. Acceleration. Results. 61 </div> 62 <div id="TopBarSearch"> 63 </div> 64 </div> 65 </div> 66 <div id="Masthead"> 67 <a id="linkHome" href="/index.shtml"><span>Myelin Repair Foundation Home Page</span></a> 68<!-- <a id="linkDonate" href="https://npo.networkforgood.org/Donate/Donate.aspx?npoSubscriptionId=3396"><span>Donate to Myelin Repair Foundation</span></a> --> 69 </div> 70<div id="nav"> 71 <ul> 72 <li id="navHome"><a href="/" class="first noIndicator">Home</a></li> 73 <li id="navBio"><a href="/biomarkers/">Biomarker Research</a> 74 <ul> 75 <li><a href="/biomarkers/index.shtml" class="add-6-top"><img src="/img/bullet-arrow-white.gif" alt=">" width="5" height="7" class="menuBullet" />Role of Biomarkers in MS Research</a></li> 76 <li><a href="/biomarkers/impact_of_brain_cells_on_ms.shtml"><img src="/img/bullet-arrow-white.gif" alt=">" width="5" height="7" class="menuBullet" />Impact of Brain Cells on MS</a></li> 77 <li><a href="/biomarkers/mrf_funded_biomarker_roadmap.shtml"><img src="/img/bullet-arrow-white.gif" alt=">" width="5" height="7" class="menuBullet" />MRF-Funded Biomarker Roadmap</a></li> 78 <li><a href="/biomarkers/mrf_funded_biomarker_timeline.shtml"><img src="/img/bullet-arrow-white.gif" alt=">" width="5" height="7" class="menuBullet" />MRF-Funded Biomarker Timeline</a></li> 79 <li><a href="/biomarkers/biomarker_research.shtml" class="add-6-bottom"><img src="/img/bullet-arrow-white.gif" alt=">" width="5" height="7" class="menuBullet" />MRFâs Critical Role in <br>Biomarker Development</a></li> 80 </ul> 81 </li> 82 <li id="navNews"><a href="/mrf_impact/">MRF’s Impact</a> 83 <ul> 84 <li><a href="/mrf_impact/" class="add-6-top"><img src="/img/bullet-arrow-white.gif" alt=">" width="5" height="7" class="menuBullet" />MRF’s Impact</a></li> 85 <li><a href="/mrf_impact/research_achievements.shtml"><img src="/img/bullet-arrow-white.gif" alt=">" width="5" height="7" class="menuBullet" />Research Achievements</a></li> 86 <li><a href="/mrf_impact/reports_whitepapers.shtml"><img src="/img/bullet-arrow-white.gif" alt=">" width="5" height="7" class="menuBullet" />Research Reports & Whitepapers </a></li> 87 <li><a href="/mrf_impact/media_archives.shtml"><img src="/img/bullet-arrow-white.gif" alt=">" width="5" height="7" class="menuBullet" />Media Archives </a></li> 88 <li><a href="/mrf_impact/honoring_ben_barres.shtml" class="add-6-bottom"><img src="/img/bullet-arrow-white.gif" alt=">" width="5" height="7" class="menuBullet" />Honoring Ben Barres</a></li> 89 </ul> 90 <li id="navFAQs"><a href="/faqs-2022.shtml" class="noIndicator">FAQs</a> </li> 91 <li id="navAbout"><a href="/about/index.shtml" class="noIndicator">About Us</a> 92 <ul> 93 <li><a href="/about/" class="add-6-top"><img src="/img/bullet-arrow-white.gif" alt=">" width="5" height="7" class="menuBullet" />About Us Overview</a></li> 94 <li><a href="/about/presidents_letter.shtml"><img src="/img/bullet-arrow-white.gif" alt=">" width="5" height="7" class="menuBullet" />President’s Letter</a></li> 95 <li><a href="/about/scott_johnson.shtml"><img src="/img/bullet-arrow-white.gif" alt=">" width="5" height="7" class="menuBullet" />About Scott Johnson</a></li> 96 <li><a href="/about/executive_team.shtml"><img src="/img/bullet-arrow-white.gif" alt=">" width="5" height="7" class="menuBullet" />Our Executive Team</a></li> 97 <li><a href="/about/board_and_advisors.shtml" class="add-6-bottom"><img src="/img/bullet-arrow-white.gif" alt=">" width="5" height="7" class="menuBullet" />Board and Advisors</a></li> 98 </ul> 99 </li> 100 <li id="navDonate"><a href="/donate.shtml" class="noIndicator">Donate</a></li> 101 <li id="navContact"><a href="/contact_us.shtml" class="last noIndicator">Contact Us</a></li> 102 </ul> 103</div> 104<div id="home_banner"> 105</div> 106<div id="home_headline"> 107 <h1> 108 ACCELERATE THE NEXT GENERATION OF MS TREATMENTS 109 </h1> 110</div> 111<div style="width: 818px; margin: 20px auto 0; padding: 20px 40px; clear: both; background: rgba(0, 107, 182, 0.1);"> 112 <h2 class="cb larger"> 113 Why Biomarkers Are Critical to MS Research 114 </h2> 115 <p> 116 A biomarker is a biological sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Currently, MRI scans are the only biomarker â or measurement â used in MS research. But MRIs cannot accurately measure if a treatment truly promotes myelin repair, which represents the next generation of MS treatments. 117 </p> 118 <p> 119 To accelerate the development of new treatments, MRF is focused on identifying additional biomarkers that can be assessed via blood tests â which are faster, less invasive, lower cost and more specific than MRI. These new biomarkers will benef
119it the millions worldwide living with MS by enabling smaller and faster clinical trials. 120 </p> 121</div> 122<div style="width: 818px; margin: 20px auto 0; padding: 20px 40px; clear: both; background: rgba(247, 148, 30, 0.1);"> 123 <h2 class="cb larger"> 124 <img src="/i/photos/Scott-receives-BCG-award.webp" alt="Scott Johnson receiving BCG Innovation Award" height="248" class="photoright" style="box-shadow: 0px 2px 18px 0px rgba(0,0,0,0.3);" /> Scott Johnson receives Innovation award from Boston Consulting Group (BCG) 125 </h2> 126 <p> 127 BCG, a global consulting firm (one of the Big Three management consulting companies in the world) has named Scott Johnson as its 2025 Alumni Innovation Award Winner in recognition of the significant research results MRF has achieved under Scottâs leadership. âIâm honored to receive this award from a prestigious organization like BCG because it highlights the success of MRFâs approach to research that is helping millions of people with MS, and potentially other neurological diseases.â 128 </p> 129 <p> 130 <a href="/documents/BCG_2025_Innovation_Award_Winner_Scott_Johnson.pdf" target="_blank">Read more about the award</a>. 131 </p> 132</div> 133<div class="home_content"> 134 <div id="home_presUpdate"> 135 <h2> 136 President’s Letter 137 </h2> 138 <p> 139 <img src="/img/photo-scott-sm.jpg" alt="photo of Scott Johnson" width="92" height="88" class="photoleft" /> <strong>Dear Friends and Supporters of MRF</strong>, 140 </p> 141 <p> 142 In our drive for effective MS treatments to repair myelin, MRF continues to make strong progress on our development of a myelin repair biomarker: 143 </p> 144 <ul> 145 <li>Over the past year, we have funded important new research projects at Yale, Columbia, McGill, Cornell, and the University of Barcelona. Plus, we will be announcing additional research that will be getting underway in the coming months. </li> 146 <li>By funding all these different research projects, weâre able to test and develop multiple biomarker assays with very positive results: the research data is showing that our assays are highly accurate. </li> 147 <li>We are attracting the interest of key pharmaceuticals with our results and are currently in talks with more than a dozen companies as we work to ensure the success and wide commercial adoption of our myelin repair biomarker.</li> 148 </ul> 149 <p> 150 <strong>Iâm very excited and confident about MRFâs biomarker progress!</strong> 151 </p> 152 <p> 153 I often get asked why MRF is so focused on developing a myelin repair biomarker. The simple answer: MRF took on this difficult and daunting task because it would not have gotten done otherwise. Developing a new biomarker is expensive, takes many years, and is inherently risky. And successful development and commercialization requires collaboration between academic research and pharma, which is rare due in part due to IP-related issues. 154 </p> 155 <p> 156 So in 2017, when commercial pharma shared with us the need for a myelin repair biomarker and noted that no effort to develop one was even being contemplated, MRF answered the call! 157 </p> 158 <p> 159 We knew MRF was uniquely suited to developing a myelin repair biomarker due to our strengths and expertise: 160 </p> 161 <ul> 162 <li>As a <strong>neutral non-profit</strong>, we can bridge the gap between academic research and commercial pharma.</li> 163 <li>We have a <strong>proven 22-year track record</strong> of using scientific collaboration to mitigate risk and accelerate results based on clear measurable stretch goals and attentive management. </li> 164 <li>We have the expertise to <strong>identify and engage the top scientists</strong> in biomarker research, and the funding necessary to support their efforts. Currently we have funded a total of 41 biomarker-related studies.</li> 165 <li>We have the <strong>credibility and contacts with pharma</strong> to move biomarker assays from academic labs to commercial testing and usage.</li> 166 </ul> 167 <p> 168 <strong>As an MS patient driven and supported organization, nothing will deter our focus on achieving a myelin repair biomarker.</strong> 169 </p> 170 <p> 171 The entire MRF team is pleased and motivated by the progress we have made and the implications for accelerating myelin repair treatments to MS patients who canât afford to wait. Your support is needed for us to complete this critical endeavor! Please donate today. 172 </p> 173 <p> 174 Sincerely, 175 </p> 176 <p> 177 <img src="/i/scott_sig.jpg" alt="Scott" />
178 </p> 179 <ul class="listing"> 180 <li> <a href="/donate.shtml">Donate to our biomarker research</a> </li> 181 <li> <a href="/biomarkers/mrf_funded_biomarker_timeline.shtml">Learn more about our myelin repair biomarker research timeline.</a> </li> 182 </ul> 183 </div> 184 <div id="home_recentUpdates"> 185 <h3 class="cb"> 186 MRF Biomarker Research 187 </h3> 188 <p> 189 <strong><a href="/donate.shtml" style="font-weight: bold!important;">Generous donations</a> from supporters like you fund this critical research.</strong> 190 </p> 191 <div class="leftList"> 192 <p> 193 <span class="home-date">May 2026</span><br /> 194 MRF funds our seventh experiment with Dr. Linden at Cornell. This work will include proteomic analysis and RNA sequencing to reveal MS-specific signatures in oligodendrocyte/myelin, neuron, astrocyte, brain-endothelial, and immune-derived EV compared to Healthy Controls. In addition, it will examine the molecularly distinct profiles based on lesion activity of MS patients. 195 </p> 196 <p> 197 <span class="home-date">March 2026</span><br /> 198 MRF funds Dr. Antel at McGill University. This work builds on two prior experiments to define the proteome of EVs derived from cultured human oligodendrocytes (OLs). It will establish the conditions for purifying OL EVs for proteomics and then analyze the OL EV proteome. Based on the proteins identified, a list of commercially available antibodies for proteins that are expressed on the surface of OLs will be identified 199 </p> 200 <p> 201 <span class="home-date">February 2026</span><br /> 202 MRF funds a third experiment at the University of Barcelona. It will isolate and characterize total EVs from paired plasma and CSF samples of patients with relapsing-remitting MS and primary progressive MS, and non-inflammatory neurological controls (individuals with headache and normal MRI). 203 </p> 204 <p> 205 <span class="home-date">July 2025</span><br /> 206 MRF funds Dr. Shur at Columbia University to identify microglial EV biomarkers in MS using CSF and iPSC-microglia. He will isolate and enrich extracellular vesicles (EVs) from the CSF of MS patients and healthy controls then perform targeted gene expression analysis. This will allow comparison to gene expression profiles among healthy controls, stable MS patients, and progressive MS patients. 207 </p> 208 <p> 209 <span class="home-date">May 2025</span><br /> 210 MRF funds a follow-up experiment at Yale to enable, via a specific exosome-based biomarker signature, earlier and more accurate detection of MS progression, which in turn allows for more timely treatment interventions, better clinical trial design, and, ultimately, the development of more effective therapies for progressive MS. 211 </p> 212 <p> 213 <span class="home-date">December 2024</span><br /> 214 MRF funds a study at Yale University that uses plasma-derived exosomes. Identifying an exosome-based biomarker for MS progression and treatment responses would constitute a major advance in MS patient care and clinical trials by allowing for a more precise patient selection and providing additional outcome measures. 215 </p> 216 <p> 217 <span class="home-date">September 2024</span><br /> 218 MRF organizes and conducts a very successful Myelin Repair Biomarker Symposium to summarize the state of the art and inform pharmaceutical companies with myelin repair drug development efforts about the capabilities of biomarkers identified by MRF. Representatives from more than 20 companies attended. 219 </p> 220 </div> 221 <div class="rightList"> 222 <p> 223 <span class="home-date">September 2024</span><br /> 224 MRF funds development of reliable, reproducible assays as a platform for biomarker discovery in multiple sclerosis progression as well as other neurological diseases. The assay isolates, from patient blood serum, EVs from brain cells, then concentrates the targeted EVs and analyzes the messages carried by those EVs. 225 </p> 226 <p> 227 <span class="home-date">March 2024</span><br /> 228 MRF funds a follow-on study at the University of Barcelona of astrocyte-derived extracellular vesicles. Astrocytes are thought to be critical for feeding both neurons and oligodendrocytes as well as creating a local environment in the brain that is conducive for repair. 229 </p> 230 <p> 231 <span class="home-date">February 2024</span><br /> 232 MRF begins a study of human CNS-endothelial cells and oligodendrocytes to determine the specific molecular signature of ETX-induced EV secretion in MS patients. Such a signature would generate a novel diagnostic tool and would help generate new therapeutic targets to inhibit and repair both ETX-induced BBB permeability and demyelination. 233 </p> 234 <p> 235 <span class="home-date">November 2023</span><br /> 236 MRF initiates a study at the Montreal Neurological Institute to identify the EV signatures, derived from microRNAs, from damaged / stressed oligodendrocytes and neurons. This will potentially lead to the discovery of clinically relevant biomarkers of disease progression. 237 </p> 238 <p> 239 <span class="home-date">September 2023</span><br /> 240 MRF funds development of reproducible assays to obtain cell type-enriched EVs from oligodendrocytes, neurons, astrocytes, and CNS-endothelial cells isolated from blood samples to access their EV cargo as indicators of myelin repair. Subsequent validation and optimization of these assays would then provide an analytic pipeline of characterized CNS, cell-specific EVs for drug development programs. 241 </p> 242 <p> 243 <span class="home-date">June 2023</span><br /> 244 Building upon MRFâs EV research results, MRF funds new assay development in Switzerland to increase the throughput of oligodendrocyte and astrocyte EV isolation and analysis from blood samples. 245 </p> 246 <p> 247 <span class="home-date">May 2023</span><br /> 248 MRF funds a new research project at Johns Hopkins University to image the iron laden microglia in the rim of chronic active MS lesions as a biomarker of remyelination or neuroprotection. 249 </p> 250 <p> 251 <span class="home-date">May 2023</span><br /> 252 MRF enters into a collaboration with NanoSomiX to use their technology to evaluate plasma-derived neuronal and oligodendrocyte EVs as biomarkers. 253 </p> 254 <p> 255 <span class="home-date">Nov 2022</span><br /> 256 Katie Whartenby, PhD, joins MRFâs research staff. For the last two decades, Katie had a lab at Johns Hopkins University focused on understanding autoimmune responses in MS. 257 </p> 258 </div> 259 </div> 260 <div class="clearit"> 261 </div> 262</div> 263<div class="home_content"> 264 <div id="rotator"> 265 <div id="rotInner"> 266<!-- --> 267 <div> 268 <p class="home_quotation"> 269 “Although hundreds of thousands of scholarly scientific articles are published every year, the FDA approves less than two-dozen new drugs a year. What's missing is the translation of all that cutting-edge science into cutting-edge cures. That's where the MRF comes in.” 270 </p> 271 <p class="home_attribution"> 272 <strong>Scott Cook</strong>, Co-Founder, Intuit 273 </p> 274 </div> 275 276<!-- --> 277 <div> 278 <p class="home_quotation"> 279 “The Myelin Repair Foundation's model—which brings together researchers and works to ensure that their work is relevant to development of patient treatments—is a critical innovation at a time when our system of drug development is looking for new ideas.” 280 </p> 281 <p class="home_attribution"> 282 <strong>Elliot Gerson</strong>, Aspen Institute and Rhodes Trust 283 </p> 284 </div> 285 286<!-- --> 287 <div> 288 <p class="home_quotation"> 289 “
289There are many foundations funding research on different diseases, but fewer that are investing in the infrastructure to manage that research more effectively.” 290 </p> 291 <p class="home_attribution"> 292 <strong>Nancy Barrand</strong>, Special Advisor for Program Development, Robert Wood Johnson Foundation 293 </p> 294 </div> 295 296<!-- --> 297 <div> 298 <p class="home_quotation"> 299 “Innovation is a decidedly social process encompassing diverse individuals, corporations, communities, networks, and regions. The work of the Myelin Repair Foundation is an excellent demonstration of these principles.” 300 </p> 301 <p class="home_attribution"> 302 <strong>John Hagel</strong>, Co-Chair, Deloitte LLC, Center for Edge Innovation 303 </p> 304 </div> 305 306<!-- --> 307 <div> 308 <p class="home_quotation"> 309 “I am drawn to new ideas that have the potential to change a market. I am inspired by the MRF's business model and advanced medical research concepts. MRF is a non-profit, but it breaks every rule and barrier to the speed of a start-up with the agility of a successful business.” 310 </p> 311 <p class="home_attribution"> 312 <strong>Samantha Fein</strong>, Managing Director, Threxy 313 </p> 314 </div> 315 316<!-- --> 317 <div> 318 <p class="home_quotation"> 319 “Unlike a lot of other organizations, the Myelin Repair Foundation really understands the intersection between academia and pharma. And if you're going to make a difference in MS, myelin repair is where you're going to have to put your efforts. We are putting efforts there.” 320 </p> 321 <p class="home_attribution"> 322 <strong>Craig Sorensen</strong>, Vice President, Vertex Pharmaceuticals 323 </p> 324 </div> 325 326<!-- --> 327 <div> 328 <p class="home_quotation"> 329 “Working with MRF is an unmistakable path for me to bring effective therapeutics — and new hope — for all patients in need.” 330 </p> 331 <p class="home_attribution"> 332 <strong>Beatrice Perotti</strong>, Ph.D., M.B.A., President and CEO, Beatrice Perotti, Inc. 333 </p> 334 </div> 335 336<!-- --> 337 <div> 338 <p class="home_quotation"> 339 “Breaking down barriers between academic research and commercial drug development will be the centerpiece of the Myelin Repair Foundation's legacy.” 340 </p> 341 <p class="home_attribution"> 342 <strong>William K. Bowes. Jr</strong>., Founder Amgen, U.S. Venture Partners 343 </p> 344 </div> 345 346<!-- --> 347 <div> 348 <p class="home_quotation"> 349 “Through our funding, we look for ways to make medical research more relevant to health improvement. MRF's leadership in transforming the research paradigm is very compelling to us.” 350 </p> 351 <p class="home_attribution"> 352 <strong>Lynne Garner</strong>, Trustee & President, Donaghue Foundation 353 </p> 354 </div> 355 356<!-- --> 357 <div> 358 <p class="home_quotation"> 359 “We view the Myelin Repair Foundation's Accelerated Research Collaboration model as just that, a transformative idea with the potential to pioneer a new approach to medical research that can speed the discovery process and lead to the development of new treatments.” 360 </p> 361 <p class="home_attribution"> 362 <strong>Carl Schramm</strong>, President and CEO, Ewing Marion Kauffman Foundation 363 </p> 364 </div> 365 366<!-- --> 367 <div> 368 <p class="home_quotation"> 369 “Not enough progress has been made, fast enough, toward effective treatments for MS. I am involved with the Myelin Repair Foundation because I really believe in the methodology: Getting the best people together to solve a really tough problem collaboratively. I truly believe that the Myelin Repair Foundation offers real hope.” 370 </p> 371 <p class="home_attribution"> 372 <strong>Julie Wainwright</strong>, Founder and CEO, SmartNow.com 373 </p> 374 </div> 375 376<!-- --> 377 <div> 378 <p class="home_quotation"> 379 “MRF's collaborative model is … definitely accelerating results. The scientists have made important advances that, if the labs had been working on their own, would have been much less likely.” 380 </p> 381 <p class="home_attribution"> 382 <strong>Brian Popko, Ph.D</strong>., University of Chicago, Director, Jack Miller Center for Peripheral Neuropathy, Associate Chair for Research, Department of Neurology 383 </p> 384 </div> 385 386<!-- --> 387 <div> 388 <p class="home_quotation"> 389 “
389I support the MRF for two reasons. Personally, I have a connection to MS: My husband has MS. But even beyond that, the vision of Myelin Repair Foundation and the method that they are proving out to get drugs to people faster is a really big vision that is important for a lot of unmet medical needs and it is exciting to be a part of it.” 390 </p> 391 <p class="home_attribution"> 392 <strong>Sharon Wienbar</strong>, Managing Partner, Scale Venture Partners 393 </p> 394 </div> 395 396<!-- --> 397 <div> 398 <p class="home_quotation"> 399 “If you just leave it to basic scientists working alone in their own labs, converting basic scientific discoveries into drugs almost never happens. Without the ARC model there is no infrastructure for accelerating drug development.” 400 </p> 401 <p class="home_attribution"> 402 <strong>Ben Barres, M.D., Ph.D</strong>., Stanford University School of Medicine, Chair, Neurobiology Department 403 </p> 404 </div> 405 406<!-- --> 407 <div> 408 <p class="home_quotation"> 409 “Disease foundations play an important role in funding early stages of research when other research and investment dollars are scarce. I am impressed by what the Myelin Repair Foundation is doing to encourage collaboration. MRF's model is novel and spot-on in terms of moving innovative research forward.” 410 </p> 411 <p class="home_attribution"> 412 <strong>Gail Maderis</strong>, President and CEO, BayBio: Northern California's Life Science Association 413 </p> 414 </div> 415 416<!-- --> 417 <div> 418 <p class="home_quotation"> 419 “The Myelin Repair Foundation has identified the best labs in a defined area and brought them together with excellent and independent minds from the pharmaceutical industry to advance the most promising ideas for novel therapeutics.” 420 </p> 421 <p class="home_attribution"> 422 <strong>Martin Raff, M.D</strong>., Emeritus Professor, University College London 423 </p> 424 </div> 425 426<!-- --> 427 <div> 428 <p class="home_quotation"> 429 “Collaborative innovation — bringing together people from different disciplines, with complementary skills — is a powerful strategy for solving complex problems. The MRF's model provides important lessons for the pharmaceutical industry, which faces a crisis of innovation in developing treatments for complex diseases.” 430 </p> 431 <p class="home_attribution"> 432 <strong>Karim R. Lakhani</strong>, Harvard Business School 433 </p> 434 </div> 435 436<!-- --> 437 <div> 438 <p class="home_quotation"> 439 “Not enough progress has been made, fast enough, toward effective treatments for MS. I am involved with the MRF because I really believe in the methodology: Getting the best people together to solve a really tough problem collaboratively. I truly believe that the MRF offers real hope.” 440 </p> 441 <p class="home_attribution"> 442 <strong>Ted Yednock</strong>, Executive Vice President, Head of Global Research, Elan Pharmaceuticals 443 </p> 444 </div> 445 446<!-- --> 447 <div> 448 <p class="home_quotation"> 449 “I believe the most striking accomplishment has been the success of the model. The thought that one could get several excellent basic scientists to work in a united effort with a clinical target in mind is really impressive... Not only has the group worked together, but there are now products of this effort. Very impressive! 450 </p> 451 <p class="home_attribution"> 452 <strong>Henry F. McFarland, M.D</strong>. (Ret.), National Institutes of Health 453 </p> 454 </div><!-- /#rotInner --> 455 <div class="clearit"> 456 </div> 457 </div> 458<!-- /#rotator --> 459 </div> 460 <div class="clearit"> 461 </div> 462</div> 463<!-- 464 <div id="home_donate"> 465 <h1> 466 Help us deliver a myelin repair treatment to MS patients 467 </h1> 468 <h6> 469 <a href="https://npo.networkforgood.org/Donate/Donate.aspx?npoSubscriptionId=3396" class="pointerLinks">Donate Today</a> 470 </h6> 471 </div> 472 --> 473<div id="FooterContainer"> 474 <div class="footer"> 475<p> 476 <strong>The Myelin Repair Foundation is a 501(c)(3), non-profit, tax-exempt charitable organization.</strong> 477</p> 478<p> 479 Photos by: Babuljak Photography 480</p> 481<p>
482 Copyright © 2002 - 483
483<script language="JavaScript1.2"> 484<!-- Begin 485var time=new Date(); 486var year=time.getYear(); 487if (year < 2000) 488year = year + 1900; 489document.write(year); 490// End --> 491 </script>
491 492 Myelin Repair Foundation. All rights reserved. Send <a href="mailto:[email protected]">email</a> to Myelin Repair Foundation. 493</p> 494<p style="text-align:left;font-size: 80%; margin: 10px 150px; line-height: 1.3em;">The content on this webpage is offered for informational purposes only. The information is not provided for the purpose of giving medical advice or recommending specific treatment options for any medical condition or health problem. You should never use the content of the webpage or any other information located on the website as a substitute for a thorough and complete discussion with your doctor about a medical condition or health problem you may have, and you should not rely on the materials in the websites when choosing a treatment plan or evaluating any other medical advice regarding any disease or medical condition. The Myelin Repair Foundation strongly urges you to consult one or more licensed physicians who are trained to diagnose and treat the symptoms of MS and other neurological diseases. The Myelin Repair Foundation makes no warranties whatsoever, express or implied, regarding the accuracy, completeness, timeliness, or usefulness of any information contained or referenced on the website. Health-related information and technology change frequently and therefore information contained in the website may be outdated, incomplete or incorrect. The Myelin Repair Foundation does not assume any risk whatsoever for your use of the information contained on the website and your use of the website and the materials contained herein
494is at your own risk.</p> 495<!-- 496<p> 497 Glial cell image copyright © 2006 Hybrid Animation. Photo credits: Sharon Hall Photography. Video credits: Tom Wohlmut (Wohlmut Media Services). 498</p> --> 499<!-- Global site tag (gtag.js) - Google Analytics -->
vendor: 64 bytes, lines 499-500
499 500<script async src="https://www.googletagmanager.com/gtag/js?id=
500UA-7522342-1
vendor: 12 bytes, line 500
500"></script>
501<script> 502
vendor: 134 bytes, lines 502-506
502window.dataLayer = window.dataLayer || []; 503 function gtag(){dataLayer.push(arguments);} 504 gtag('js', new Date()); 505 506 gtag('config', '
506UA-7522342-1
vendor: 4 bytes, line 506
506');
507</script>
vendor: 1 bytes, line 507
507
508<script> 509 (function() { 510 var $gallery = new SimpleLightbox('.gallery a', {}); 511 })(); 512</script>
512 513 </div> 514</div> 515</body> 516</html>
Line numbers count LF bytes from the start of the resource, as the search results do. Vendor segments are library code the classifier recognised; they are stored but not indexed. Bytes are shown as Latin1 characters, one per byte.